Europe’s New Health Technology Assessment Framework: Progress or Pitfall?
On January 12, 2025, the European Union’s Health Technology Assessment Regulation (HTAR) came into force, introducing a centralized framework
The CAIA in Biotech and Pharma: A Linear Compass for a Tangled Jungle
The Chartered Alternative Investment Analyst (CAIA) designation positions itself as the key to unlocking the mysteries of hedge funds, private
The CFA in Biotech and Pharma: Predicting the Unpredictable with the Wrong Tools
The Chartered Financial Analyst (CFA) designation once sat atop the financial world like a gold standard minted for modern markets.
Fun with Funds: Exploring the XBI
Welcome back to Fun with Funds, where we break down intriguing financial vehicles in plain English. Today’s guest is
SPACs: Biotech’s Shortcut to the Big Time, or Just a Shortcut to Disaster?
SPACs and Biotech: A Cautionary Tale
In recent years, Special Purpose Acquisition Companies (SPACs) emerged as a popular alternative to
The Davos Effect: Is It About the Debate, the Clout, or Just the View?
Davos in January. The snow-dusted mountains, the high-altitude air of importance, and the collective hum of thousands of people all
The Problem with Timid Founders: Breaking Free from the Research Mindset
It is a truth universally acknowledged that a brilliant researcher in possession of a good idea is often too timid
A Case Study on IP-Backed Finance: Lessons from South Korea
A few years ago, if someone had told me you could walk into a bank, lay a patent on the
Welcome to Medicocristan: Why Mediocrity Is the Enemy of Breakthroughs
Medicocristan is a place where mediocrity reigns supreme. Its streets are orderly, its people are risk-averse, and its leaders champion
Consulting: The Final Refuge of the Corporate Castaway
It’s a tale as old as the severance check. A veteran employee—newly liberated from the corporate mothership—decides
